Most Active Stories
- Four Concerts Scheduled In Expanded, Larger Back Porch Music Series In Durham
- Duke Professor Carries On Tradition Of Black Radical Poetry
- First Openly Lesbian Presbyterian Pastor, One Year In
- As Costa Concordia Sank, Newlyweds Allowed Others To Take Life Boats First
- Why Do Political Activists Burn Out?
Hosts, Reporters and Producers
Business & Economy
Tue October 4, 2011
NC-Based PPD Sold
North Carolina’s clinical trials industry is seeing a major shift. The latest example is the purchase of Wilmington-based P-P-D.
Pharmaceutical Product Development or P-P-D was acquired by two private equity firms for a whopping 3-point-9-billion dollars. It’s said to be one of the largest private equity deals of the year. The pharmaceutical industry outsources clinical research and testing to companies like P-P-D. Kevin Schulman is director of the Health Care Sector Management Program at Duke’s Fuqua School of Business. He says like pharmaceutical companies – the clinical research industry is shrinking.
Kevin Schulman: "When Glaxo and SmithKline were separate, they were two separate clients for PPD. And Pfizer and Wyeth were separate, they were two separate clients. As those firms merged there were fewer and fewer clients for PPD to work with."
Wall Street liked the P-P-D announcement. Shares jumped 30-percent